At a glance
- Follistatin 344 is a secreted binding-protein isoform that can bind activins and related TGF-beta-family ligands, including myostatin. It is a regulatory protein—not a receptor-selective myostatin inhibitor.
- Recombinant follistatin 344 is not an approved muscle-building medicine. Most direct evidence comes from cells and animals; gene-therapy studies or endogenous follistatin measurements are not equivalent to a lyophilized recombinant protein vial.
- Measure activin A, myostatin, and other ligand interactions rather than assuming selectivity for GDF-8 alone.
- Use receptor-SMAD and muscle-cell endpoints together to connect ligand binding with downstream biology.
What FOLLISTATIN 344 is—and what the name does not establish
Follistatin 344 is a secreted binding-protein isoform that can bind activins and related TGF-beta-family ligands, including myostatin. It is a regulatory protein—not a receptor-selective myostatin inhibitor.
Follistatin wraps around certain ligands and prevents them from reaching activin type II receptors. In plain language, it can remove several signalling messages at once, which is why muscle-related effects and off-target reproductive or endocrine effects must be considered together.
Questions to settle before interpreting a result
A useful FOLLISTATIN 344 study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Measure activin A, myostatin, and other ligand interactions rather than assuming selectivity for GDF-8 alone.
- Use receptor-SMAD and muscle-cell endpoints together to connect ligand binding with downstream biology.
- Distinguish recombinant protein exposure from follistatin gene transfer, endogenous expression, and shorter isoforms.
How to read the FOLLISTATIN 344 evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Preclinical evidence
- Design
- Blocking activin-family ligands can change muscle phenotypes
- Finding
- Animal and genetic studies show that higher follistatin activity can increase muscle mass in selected models. The same broad ligand binding can affect reproductive and other systems.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Selectivity caution
- Design
- Follistatin binds more than myostatin
- Finding
- Activins and related ligands contribute to endocrine, reproductive, inflammatory, and tissue biology. A muscle endpoint alone can miss important pathway effects.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Format distinction
- Design
- Protein, gene therapy, and endogenous levels are not equivalent
- Finding
- They produce different location, duration, folding, and exposure. Evidence should stay attached to the exact experimental format.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
Recombinant follistatin 344 is not an approved muscle-building medicine. Most direct evidence comes from cells and animals; gene-therapy studies or endogenous follistatin measurements are not equivalent to a lyophilized recombinant protein vial.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- Follistatin gene delivery enhances muscle growth and strength in nonhuman primatesPubMed-indexed gene-delivery study · 2009
Primary gene-delivery research using a defined FS344 expression system. A gene vector, endogenous expression, and a supplied protein vial are not equivalent formats.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote for FOLLISTATIN 344
This compound is not currently stocked. Add it to your five-choice catalogue ballot.